iBio Announces Advancement of COVID-19 Vaccine Program...


crweworld.com | 2020-03-27 00:36 UTC

NEW YORK, March 26, 2020 -- iBio, Inc. (NYSE AMERICAN:IBIO) announced that immunization studies for its SARS-CoV-2 Virus-Like Particle program are proceeding at Texas A&M University System laboratories.

By socnet on 2020-03-27 00:36 UTC
  • Need an account?  
    or